𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Development of a pilot process for the production of alfalfa peptide isolate

✍ Scribed by Nathalie Prévot-D'Alvise; Christine Lesueur-Lambert; Anne Fertin-Bazus; Bertrand Fertin; Pascal Dhulster


Publisher
Wiley (John Wiley & Sons)
Year
2003
Tongue
English
Weight
216 KB
Volume
78
Category
Article
ISSN
0268-2575

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

Enzymatic membrane reactors are widely used to produce protein hydrolysates. During the past few years, leaf extracts have been recognised as a good source of high quality protein. The interest in alfalfa protein concentrate (APC), a hydrophobic protein with excellent functional and nutritional properties, is due to its abundance, to its amino acid composition and to its ribulose 1,5‐biphosphate carboxylase–oxygenase content. In order to use this potential protein source in various fields (food, pharmaceutical and cosmetic industries), a pilot process for APC hydrolysis in a continuous stirred tank membrane reactor (CSTMR) was carried out. At pH 9.5 and 40 °C, the hydrolysis of APC (30.6 g dm^−3^) by Delvolase (2.4 g dm^−3^) with a residence time of 180 min, gave a conversion of 759 g kg^−1^ protein at steady state. Coupling the reactor with an inorganic ultrafiltration membrane (Carbosep M5) with a 10 kDa nominal molecular weight cut‐off (NMWCO), allowed production of a soluble and reproducible peptide permeate with 23 g dm^−3^ of hydrolysed protein. Phenolic compounds, responsible for the brown colour of the permeate, were removed at pH 5.0 and room temperature by anion‐exchange chromatography using Amberlite IRA900Cl, with a yield of 920 g kg^−1^. After electrodialysis and spray‐drying of the decolorised permeate, an alfalfa peptide isolate (API) was obtained. It was soluble over the full pH range and its amino acid composition was comparable to that of the FAO/WHO standard. It could be used as a protein supplement in human diets and other fields. Copyright © 2003 Society of Chemical Industry


📜 SIMILAR VOLUMES


Development of a production process for
✍ István Huszár; He Youfeng; Jürg Jegge; Regin Weinreich 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 French ⚖ 52 KB

Among the generator produced positron emitters, recently 75-sec "Rb found widespread interest in nuclear cardiology. For this reason, some suppliers of radiopharmaceuticals asked about a production of its parent nuclide 25.5-d "Sr at Paul Scherrer Institute.

Development of a suspension copolymeriza
✍ Carlos M. Cordoví; A. De Lucas; A. Durán; J. F. Rodríguez 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 210 KB 👁 1 views

Copolymers of MMA-STY with the suitable composition, particle size distribution, and molecular weight distribution for its medical application as bone cements have been obtained by means of suspension copolymerization. The influence of the stirring rate on the final mean particle size has been estab

Development of a denaturation/renaturati
✍ Anu Jääskeläinen; Tero Soukka; Urpo Lamminmäki; Teemu Korpimäki; Marko Virta 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 505 KB

## Abstract Recently, we presented a simple method for generating biological functional protein‐based nanoparticles that are ready for use as label agents in bioaffinity assays (Jääskeläinen et al., 2007 Small 3:1362–1367). In this process, the particle shell (ferritin protein) and binding molecule